**Novel and Enhanced Efficacy of Glyco-Engineered Rice Cell-Produced Trastuzumab**

Jun-Hye Shin1,2, Sera Oh3,4, Seok-Yong Lee3,4, Mi-Hwa Jang2, Chanhong Min4, Hilal Begum1, Jong-Chan Kim1, Kap-Yul Lee1, Han-Bin Oh5, Matthew J. Paul 6, Julian K-C Ma6, Ho-Shin Gwak7, Hyewon Youn3,4\*, Seong-Ryong Kim1,2\*

1Department of Life Science, Sogang University, Seoul, Republic of Korea; 2PhytoMab Co. Ltd., South Korea; 3Department of Nuclear Medicine, Cancer Imaging Center, Seoul National University Hospital, Seoul, South Korea; 4Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea; 5Department of Chemistry, Sogang University, Seoul, South Korea; 6Hotung Molecular Immunology Unit, Institute for Infection & Immunity, St George's University of London, Cranmer Terrace, London, SW17 0RE, United Kingdom; 7National Cancer Center Korea, Goyang-si, Kyunggi-do, South Korea

\*Author for Correspondence:

Seong-Ryong Kim, Ph.D.

Phone: +82-2-704-8456

Email: sungkim@sogang.ac.kr

Orcid ID: 0000-0003-4901-7260

Hyewon Youn, Ph.D.

Phone:+82-2-3668-7026

E-mail: [hwyoun@snu.ac.kr](mailto:hwyoun@snu.ac.kr)

ORCID ID: 0000-0003-1006-2689

**Abstract**

To date, therapeutic monoclonal antibodies (mAbs) have mostly been produced using Chinese hamster ovary (CHO) cells. Although the CHO platform has various advantages, there are concerns about the risk of contamination with zoonotic pathogens and the high cost. A plant-based expression system has been proposed as an alternative platform for several decades. To address the immunogenicity concerns associated with plant-specific N-glycans, eight genes (*α1,3-FucT/β1,2-XylT/β1,3-GalT/α1,4-FucT/Hexo1/Hexo2/Hexo3/Hexo4*) involved in N-glycosylation were modified in rice (*Oryza sativa*) using the CRISPR/Cas9 system. The glyco-engineered cell lines, PhytoRice®, contained a predominant N-glycan structure of GnGn (G0). The gene for codon-optimized trastuzumab (TMab) was then introduced into PhytoRice® through *Agrobacterium* co-cultivation. Selected cell lines were cultured in suspension, and the TMab produced was purified from the spent media. The amino acid sequence of the TMab produced by PhytoRice® (P-TMab) was identical to that of TMab. The inhibitory effect of P-TMab on the proliferation of the BT-474 cancer cell line was significantly enhanced at concentrations above 1 µg/ml. P-TMab bound to a rare FcγRIIIa variant, FcγRIIIa-F158, more than 2.7 times more effectively than TMab. The ADCC efficacy of P-TMab against JurKat cells was 2.6 times higher than that of TMab in an *in vitro* ADCC assay. Furthermore, P-TMab demonstrated increased specific tumor uptake with much less liver targeting compared to TMab in a xenograft assay using the BT474 mouse model. These results suggest that the glyco-engineered PhytoRice® could be an alternative platform for mAb production compared to current CHO cells, and P-TMab has a novel and enhanced efficacy compared to TMab.

Keywords: Rice, N-glycosylation, Plant specific N-glycan, Glyco-engineering, Suspension cell, PhytoRice, Trastuzumab, P-TMab

**Introduction**

Monoclonal antibodies (mAbs) have become the dominant class of newly developed drugs and the best-selling drugs worldwide in the pharmaceutical market since the first mAb was approved by the United States Food and Drug Administration (US FDA) in 1986 (Ecker *et al*., 2015; Lu *et al*., 2020). To date, most therapeutic mAbs are known to target cancer cells and autoimmune diseases (Stelter *et al*., 2020). Of these, TMab is a well-known blockbuster mAb widely used for the treatment of breast and gastric cancer. Currently, mAb therapeutics are mostly produced using Chinese Hamster Ovary (CHO) cell cultures, which have high productivity. However, there are several issues, such as the high cost of the cell culture media and the risk of contamination with pathogens that cause zoonotic diseases, leading to high production costs (Shanmugaraj *et al*., 2020).

Breast cancer has been reported as the most commonly occurring cancer in women, causing more than 500,000 deaths worldwide per year (Komarova *et al*., 2019). Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which affects approximately 20-30% of all breast cancer patients, is characterized by the overproduction of HER2 (Komarova *et al*., 2019). The HER2 protein in breast and gastric cancer cells has been identified as a validated therapeutic target, as demonstrated in the functional study of TMab (Cobleigh *et al*., 1999; Slamon *et al*., 2001; Bang *et al*., 2010). Currently, the combined use of chemotherapy and TMab is considered the primary medical treatment for HER2-positive breast cancer (Hudis, 2007). However, its effectiveness is limited in treating metastatic HER2-positive breast cancer and metastatic breast cancer with low HER2 expression (Komarova *et al*., 2019).

The modes of action of TMab are categorized into non-immune and immune-mediated mechanisms (Musolino *et* *al*., 2022). The non-immune mechanism results from the binding of antibody fragment antigen-binding (Fab) domains to HER2 receptors, leading to the antiproliferative effects of cancer cells by perturbing HER2-signaling (Slamon *et al*., 2001). The immune response is initiated by the physical interaction of the fragment crystallizable (Fc) domains of tumor cell-bound antibodies with Fc receptors (FcRs) on the surface of immune cells. This interaction leads to the elimination of cancer cells through effector functions such as antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP), which are the primary functions of antibody therapeutics (Arnould *et al*., 2006; Gül and van Egmond, 2015). The immune-mediated mechanism of antibody therapeutics relies on N-glycosylation, which plays an important role in affecting the binding affinity to FcRs of immune cells. While normal fucosylated TMab demonstrated a significant reduction in effector functions such as ADCC (Arnould *et al*., 2006), afucosylated TMab exhibited significantly improved ADCC effector efficacy, resulting in superior suppression of cancer cell growth (Suzuki *et al*., 2007; Junttila *et al*., 2010; Fiedler *et al*., 2018). Similarly, the recently approved Margetuximab has also demonstrated enhanced binding affinity to FcγRIIIa (CD16A) and reduced binding affinity to FcγRIIb (CD32B), thereby improving ADCC function (Nordstrom *et al*, 2011; Rugo *et al*., 2021). These results strongly indicate the potential for developing a biobetter by enhancing the effector function of the Fc domain.

For a long time, alternative platforms to CHO-based platforms have been sought, and the plant-based platform has gained attention due to its merits, such as being free from zoonotic microorganisms and cost-effectiveness (Chen and Davis, 2016). Thus, the plant cell-based Elelyso® (enzyme therapeutics for Gaucher's disease) and Elfabrio® (enzyme therapeutics for Fabry disease), as well as the tobacco leaf-based Covifenz® (COVID-19 vaccine), have been approved to date (Fox, 2012; Hughes *et al*., 2023; Mirasol, 2022; Ruocco and Strasser, 2022).

For the development of plant-based mAb therapeutics, consideration should be given to the post-translational modification (PTM) of the mAb protein, as it is influenced by plant-specific N-glycosylation (Castilho and Steinkellner, 2012). The plant-specific N-glycans may cause immunogenicity in humans (Gomord *et al*., 2010; Santos *et al*., 2016). Various studies using RNAi or CRISPR/Cas9 have been conducted to reduce or eliminate plant-specific N-glycans (Cox *et al*., 2006; Shin *et al*., 2011; Hanania *et al*., 2017; Mercx *et al*., 2017; Stelter *et al*., 2020; Göritzer *et al*., 2022; Herman *et al*., 2023). However, there are no reports of complete elimination of plant-specific N-glycans.

In this study, rice cell lines have been developed to completely remove plant-specific N-glycans using CRISPR-Cas9-based GlycoPhyto technology, which includes Fc glyco-engineering and repeated selection of cell lines with Sanger sequencing. The established PhytoRice® cell lines exhibited highly uniform GnGn (G0) N-glycan in the secreted proteins, as well as in the total soluble proteins. Using the PhytoRice® cell line, a TMab was successfully produced, purified, and named P-TMab. P-TMab specifically binds to the HER2 receptor with enhanced binding affinity. Furthermore, the binding affinity to FcγIIIa variants and the ADCC activity of P-TMab were significantly improved compared to those of TMab. This suggests that P-TMab has the potential to be a biobetter, enhancing the effector function of the Fc domain.

**Results**

**Establishment of glyco-engineered rice cell lines**

β1,2-XylT and *α1,3-FucT* are known to exist as single genes in the rice genome (Takano *et al*., 2015; Harmoko *et al*., 2016; Jung *et al*., 2021). In addition, a rice *β1,3-GalT* gene was recently elucidated (Jung and Kim, 2023). However, there are no reports about other genes involved in plant-specific N-glycosylation, such as *α1,4-FucT* and hexosaminidase (HEXO) genes, in the rice. To identify candidate genes in rice, a BLAST search was conducted using the amino acid sequences of orthologous genes confirmed in Arabidopsis (Strasser *et al*., 2007; Liebminger *et al*., 2011). In the results, LOC\_Os12g07290, LOC\_Os05g02510, and LOC\_Os03g11980 were identified as putative *α1,4-FucT, HEXO1*, and *HEXO2* genes, respectively (Table S1). Interestingly, both LOC\_Os01g66700 and LOC\_Os05g34320 were identified as *OsHEXO3* candidates, which is unlike *Arabidopsis* and *Nicotiana benthamiana*, which have a single *HEXO3* gene (Strasser *et al*., 2007; Liebminger *et al*., 2011; Shin *et al*., 2017). Thus, four *HEXO* gene candidates (LOC\_Os05g02510 as *HEXO1*, LOC\_Os03g11980 as *HEXO2*, LOC\_Os01g66700 as *HEXO3*, and LOC\_Os05g34320 as *HEXO4*) were ultimately identified in the rice genome (Table S1).

To knock out a total of 8 genes (*β1,2-XylT, α1,3-FucT, β1,3-GalT, α1,4-FucT*, and 4 putative *HEXO* genes) simultaneously, one specific target sequence per gene was selected using the CRISPR-P gRNA design tool (Liu *et al*., 2017). As shown in Table 1, all selected target sequences were located in the 5' region of the coding sequence of each gene (Exon 1 or 2) to increase the possibility of causing a nonsense mutation via insertion or deletion (INDEL). Two expression cassettes containing polycistronic gRNA sequences, each consisting of four target sequences, driven by the rice U6 promoter, were synthesized and inserted into a CRISPR-Cas9 vector, resulting in the generation of pPM101 (Fig. 1a). After rice callus transformation mediated by *Agrobacterium* carrying pPM101, hygromycin-resistant calli were selected, and the genomic regions around the target sequence were amplified using PCR. The PCR products were sequenced and then analyzed using ICE analysis available at https://ice.synthego.com/#/. After several rounds of repeated selection, the callus line #1-12-20-11 was ultimately chosen for its editing efficiency (Fig. S1a), and confirmed by immunoblotting using anti-β1,2-XylT and anti-α1,3-FucT antibodies (Fig. S1b). As indicated in Figure S1A, the gene editing efficiency was nearly 100% for all genes except for *β1,3-GalT* (57%) and *α1,4-FucT* (23%). The callus from line #1-12-20-11 was further divided into single-cell clones after suspension culture and microscopic observation were conducted. Finally, two independent cell lines, PMC1 and PMC2, were selected based on the extent of genome editing and their N-glycan profile (Fig. 1b). The PMC1 and PMC2 calli showed a tendency to grow normally, but they were very fragile and fine compared to the wild-type callus (data not shown). In addition, plant regeneration failed in the KO cells, a phenomenon consistent with previous reports on the knockout of genes associated with N-glycosylation (Fanata *et al*., 2013; Jung *et al*., 2021).

**Molecular characterization of the glyco-engineered cell lines**

For the PMC lines, the N-glycans of proteins and the loci of T-DNA insertion were examined. The N-glycans of secreted proteins in the spent media, as well as the total soluble proteins of the suspension cells, were analyzed using mass spectrometry (MS). For the PMC1 cell line, the proportion of GnGn was 97.4% for the secreted proteins, compared to 80.8% for the total soluble proteins (Fig. 1c and Table S2). In PMC2, the proportion of GnGn in total soluble proteins and secreted proteins was 92.3% and 81.9%, respectively (Table S2). These results indicate that the plant-specific N-glycans were eliminated in the cell lines (Fig. 1c and Table S2).

For future use of the PMC cell lines, the characteristics of the cells should be identified. Therefore, the copy number of T-DNA and the insertion site in the rice genome were investigated using inverse PCR. For the PMC1 cell line, a copy of T-DNA was identified in the 4th intron of LOC\_Os01g29409 on chromosome 1 (Fig. S2a). For the PMC2 line, two T-DNAs were identified at the loci of LOC\_Os01g29409 and the intergenic region between LOC\_Os02g44780 and LOC\_Os02g44810 (Fig. S2b). No correlation between T-DNA copy number and genome editing efficiency was observed. The genome-edited N-glycan-engineered cells were named and registered as PhytoRice. The single copy T-DNA tagged PMC1 line was further used for the production of TMab.

**Expression of TMab in PhytoRice**®

To produce TMab immunoglobulin in PhytoRice®, both the heavy chain and light chain of TMab were codon-optimized, synthesized, and then cloned into a binary vector under the *Ramy3D* promoter, resulting in the creation of pPM102 (Fig. 2a). PhytoRice® cells were transformed using *Agrobacterium tumefaciens* LBA4404 containing pPM102. Transgenic calli were selected on agar plates containing phosphinothricin (PPT), and genomic DNA PCR was conducted using primers for the light chain gene of TMab. As shown in Figure 2b, the expected 0.7 kb-sized bands were detected in the calli, and those positive calli were subjected to western blotting using a human IgG antibody. About 150 kDa bands corresponding to the size of TMab were detected on the non-reducing SDS-PAGE (Fig. 2c). The expression level of TMab in each transgenic callus varied, and among the calli examined, line #10 and #11 were selected for suspension cell culture.

**Establishment of a TMab producing cell line**

Among lines #10 and #11, line #10 exhibited a higher expression of TMab in the suspension culture (data not shown) and was designated as PHYTO101. The PHYTO101 callus was suspended in N6 liquid media containing 2 mg/L of 2,4-D and 0.02 mg/L of kinetin. After establishing the suspension cell culture, PHYTO101 cells that had been grown for 7 days in the growth media were transferred to media without sucrose and then incubated for an additional 7 days. TMab expression was detected in the spent media after Day 2 and reached its highest level on Day 5 (Fig. 2d).

To quantify the amount of TMab produced on Day 5, an enzyme-linked immunosorbent assay (ELISA) was performed using the cells and the spent media from Day 5. Similar levels of TMab were detected in both the cells and the media, at 47.2 and 44.3 mg/L, respectively (Fig. 2e). Therefore, the productivity of TMab in Phyto101 was approximately 91.5 mg/L.

**Characterization of TMab produced from PHYTO101**

The TMab produced from the PHYTO101 cell line was purified using chromatography and named P-TMab. As shown in Fig. 3a, a 150 kDa band was observed under non-reduced conditions, while bands of 50 kDa and 25 kDa were observed under reduced conditions. To confirm whether the amino acid sequence of P-TMab is the same as that of TMab, full-length amino acid sequencing was performed using LC/MS/MS analysis of trypsin- or Glu-C-treated heavy and light chains of P-TMab and TMab. As shown in Table S3, the sequences of P-TMab separated by LC/MS were 100% matched with those of TMab at the peptide level. Following additional LC/MS/MS analysis, the sequence coverages for TMab and P-TMab were found to be up to 94% and 93.7% respectively at the single amino acid level. It was also observed that the amino acid sequence of P-TMab was identical to that of TMab (Table S4).

The secondary and tertiary structures of P-TMab were compared with those of TMab using circular dichroism (CD). As depicted in Figure 3b, the Far-UV CD absorption spectra, measured in the range from 195 to 250 nm, exhibited a similar pattern between P-TMab and TMab. They displayed the characteristic features of proteins with high β-sheet content, including a positive band around 202 nm and a negative band at approximately 218 nm (Moro Pérez *et al*., 2019). The near-UV CD spectra of P-TMab obtained in the 250-350 nm interval also showed similarity to that of TMab (Fig. 3c), indicating that P-TMab has a similar structure to TMab in its native condition.

**P-TMab exhibits a novel N-glycan profile**

TMab is well-known to contain N-glycan linked to the asparagine residue at position 300 (ASN300) in the CH2 domains (Nebija *et al*., 2014). N-glycan analysis of P-TMab using the UPLC-FLD method revealed that the GnGn (G0) form was exclusively present in P-TMab, while heterogeneous N-glycan forms were detected in TMab (Fig. 4 and Table S5). This indicates the complete elimination of plant-specific N-glycan in P-TMab. Moreover, 90.5% of the N-glycan found in TMab consists of various fucosylated forms, with only 9.5% in the afucosylated form (G0-GN, G0, and G1 at 0.7%, 5.4%, and 3.4%, respectively). In contrast, all N-glycan found in P-TMab was in non-fucosylated form, such as G0 and G0-GN, which accounted for 95.5% and 4.5%, respectively (Table S5).

**P-TMab physically bound to HER2 inhibits the proliferation of cancer cells *in vitro* in BT-474 cells**

TMab blocks HER2-mediated cell signaling by binding to HER2, thereby inhibiting cancer cell proliferation (Musolino *et al*., 2022). The degree of binding affinity to HER2 correlates with its functional activity. We utilized Bio-layer interferometry (BLI) to measure the binding affinity and confirm the physical interaction between P-TMab and HER2. As shown in Figure 5A, the equilibrium dissociation constant (*KD*) values of P-TMab and TMab were 0.07 nM and 0.08 nM, respectively. This indicates a slightly higher binding affinity of P-TMab to HER2 compared to TMab. Moreover, O-TMab, produced from transgenic wild-type rice, exhibited a reduced binding affinity to HER2 with a *KD* value of 0.13 nM (Fig. 5a).

We investigated the antiproliferative effect of P-TMab on breast cancer cells *in vitro*. As shown in Figure 4b, P-TMab inhibited the growth of BT-474 cells. The antiproliferative effect of P-TMab was similar to that of TMab at a lower concentration of 1 µg/ml. However, at concentrations higher than that, the antiproliferative effect of P-TMab was more pronounced than that of TMab (Fig. 5b). O-TMab exhibited a similar antiproliferative effect to that of TMab at all concentrations tested (Fig. 5b and Fig. S3). Taken together, the results indicate that both P-TMab and O-TMab have the same mechanism of action as TMab, and P-TMab exhibits an enhanced anti-tumor effect.

**Binding affinity of P-TMab to FcγRIIIa variants was significantly enhanced**

The immune-mediated mechanism of antibody therapeutics is well known to involve N-glycosylation, which impacts the binding affinity to Fcγ receptors on immune cells. Two common alleles of the FcγRIIIa (CD16a) gene encode two variants that differ at position 158, either valine (V158) or phenylalanine (F158). Whereas FcγRIIIa-V158 has a high affinity for human IgG1, FcγRIIIa-F158, which is a major allele of FcγRIIIa, shows poor binding affinity to IgG1 (Koene *et al*., 1997; Pereira *et al*., 2018).

The binding affinity of P-TMab to FcγRIIIa variants was assessed using Surface Plasmon Resonance (SPR). Whereas the *KD* of TMab to the FcγRIIIa-F158 was 604 nM, the *KD* value of P-TMab was 222 nM. This indicates that the binding affinity of P-TMab to FcγRIIIa-F158 is 2.7 times higher than that of TMab (Fig. 6a). The *KD* value of P-TMab and TMab to FcγRIIIa-V158 were 61 nM and 130 nM, respectively (Fig. 6a). These results suggest that P-TMab could enhance the anti-cancer effectiveness through improved Fc effector function.

**Enhanced ADCC efficacy of P-TMab *in vitro***

To investigate whether P-TMab enhances ADCC efficacy, we conducted an *in vitro* ADCC assay. As shown in Figure 6b, the intensity of luminescence tends to increase as the amount of both mAbs are increased. Notably, under all the examined concentration conditions, cells treated with P-TMab exhibited significantly higher luminescence compared to cells treated with TMab (Fig. 6b). The EC50 values for P-TMab and TMab were 17 ng/ml and 45 ng/ml, respectively (Fig. 6b). In contrast, the luminescence intensity was significantly lower in O-TMab-treated cells than in TMab-treated cells (Fig. S4). The results strongly indicate that P-TMab outperforms TMab in terms of ADCC efficacy, primarily by enhancing its binding affinity to FcγRIIIa.

**P-TMab was more targeted to tumor**

To examine the *in vivo* distribution of P-TMab, we conducted SPECT/CT imaging using 111Indium-labeled antibodies in a HER2-positive BT474 tumor model. After labeling the antibody with the radioactive isotope 111Indium, the efficiency of the labeling process was determined using thin-layer chromatography. The results showed that the labeling efficiency was almost equal for both antibodies (Fig. 7a). 111In-labeled TMab or P-TMab antibodies were administered via tail vein injection to mice bearing BT-474 tumors. The results indicated a significant increase in antibody uptake in the tumor for both P-TMab and TMab-treated mice for up to 48 hours after antibody injection (Fig. 7b). Remarkably, the uptake pattern of P-TMab in the liver differed from that of TMab. P-TMab exhibited reduced liver uptake compared to TMab starting from 6 hours after antibody injection. Furthermore, P-TMab was scarcely detected in the liver after 48 hours, while TMab was still detectable in the liver at the same time point (Fig. 7b). The results indicate that P-TMab might be more specifically targeted to tumors by minimizing liver uptake.

**Discussion**

Because nearly all therapeutic proteins undergo glycosylation, it is important to utilize a platform capable of conducting post-translational modification (Dammen-Brower *et al*., 2022). It is well-known that plants undergo a post-translational modification process similar to that of mammals. Therefore, plant-based platforms are emerging as alternative platforms to animal cell-based platforms for this reason. In addition, the plant-based manufacturing system is expected to reduce production and purification costs compared to the animal cell culture system, due to the lower cost of plant culture medium (Doran 2006; Kwon *et al*., 2009). Several techno-economic analyses have shown that plant-based systems could be competitive with the current CHO cell culture system (Holtz *et al*., 2015; Buyel *et al*., 2017; Corbin *et al*., 2020; Ridgley *et al*., 2023). Over three decades, plant cell-based platforms have been developed, leading to successful cases such as the U.S. FDA-approved Elelyso® in 2015 and Elfabrio® last year. (Fox, 2012; Hughes *et al*., 2023). However, the plant manufacturing system has rarely been used for the production of therapeutic proteins because plants typically contain plant-specific glycans that are different from those found in humans (Ma *et al*., 2020). The plant-specific N-glycans could induce immunogenicity against IgM when injected into humans, and negatively affect the quality of therapeutic proteins. This is because N-glycans are important for protein folding, stability, and function, specifically due to protein–protein interactions (Castilho *et al*., 2018). Therefore, the humanization of N-glycan on a plant-based platform is a prerequisite for the commercialization of plant-made pharmaceuticals (PMP) (Gomord and Faye, 2004; Kwon *et al*., 2009).

N-glycosylation is a critical quality trait of biotherapeutic proteins that influences the efficacy, half-life, and immunogenicity of the drugs (Donini *et al*., 2021). In this study, we developed glycoengineered rice cell lines, called PhytoRice®, which completely eliminated all the plant-specific sugar moieties using the CRISPR-Cas9 technique (Fig. 1c). Although efforts to eliminate plant-specific N-glycans have continued, the modification of core glycans in α1,3-FucT and β1,2-XylT genes has been the primary focus (Cox *et al*., 2006; Strasser *et al*., 2008; Shin *et al*., 2011; Hanania *et al*., 2017; Mercx *et al*., 2017; Stelter *et al*., 2020; Jung *et al*., 2021; Göritzer *et al*., 2022; Herman *et al*., 2023). However, these efforts have not been sufficient to completely remove the plant-specific N-glycans (Jung *et al*., 2021). The complete removal of plant-specific N-glycans in polyploid plants, such as *Nicotiana* species, has not been reported. In this study, no N-glycans with β1,3-galactose or α1,4-fucose residues were found, despite the low gene editing efficiency of *α1,4-FucT* in both PMC cell lines (7% and 16% respectively, Fig. 1b). This suggests that the function of α1,4-FucT may be dependent on that of β1,3-GalT. Consistently, it has been reported that the knockout of *β1,3-GalT* leads to the inhibition of Lewis a epitope formation (Jung and Kim, 2023).

PhytoRice® was used to successfully produce TMab in this study. Efforts to establish plant-based monoclonal antibody (mAb) production have continued since the initial report of mAb production in plants (Hiatt *et al*., 1989; Arya *et al*., 2021). Among these efforts, two research groups have presented characterizations of TMab produced in *Nicotiana benthamiana* using a transient expression system (Grohs *et al*., 2010; Komarova *et al*., 2011; McLean, 2017). The plant-produced TMab (PMT) showed similar HER2 binding affinity and tumor-killing effectiveness to a commercial TMab in *in vitro* antiproliferation assays performed on HER2-positive breast cancer cell lines. Our research consistently showed that the TMab produced in *N. benthamiana* demonstrated *in vitro* anti-tumor efficacy similar to that of TMab (unpublished data). We also demonstrated that wild-type rice-based O-TMab and P-TMab inhibited the proliferation of HER2+ breast tumor cells by blocking HER2 signaling (Fig. 5 and Fig.S3). These findings collectively support the idea that a plant manufacturing system could be a feasible alternative for producing therapeutic mAbs with efficacy similar to animal-based counterparts. Notably, Komarova *et al*. (2011) reported that PMT more effectively inhibited the growth of xenografted tumors derived from human ovarian SKOV3 cancer cells than TMab, although the mechanism was not clear.

The effector function of IgG1 mAbs is significantly influenced by the N-glycan structure on the Fc region (Pereira *et al*., 2018). The G0 type N-glycan was predominantly identified in P-TMab (Fig. 4). The removal or reduction of fucosylation on mAbs has been the primary focus on biopharmaceutical glycoengineering. Studies on mAbs have shown that fucosylation on the Fc affects ADCC function (Umaña *et al*., 1999; Shields *et al*., 2002; Yamane-Ohnuki *et al*., 2004). The FcγRIIIa gene is known to have two common alleles that encode two variants differing at position 158: Val (V158) or Phe (F158). Among the two variants, FcγRIIIa-V158 has a higher affinity for human IgG1 (Koene *et al*., 1997; Pereira *et al*., 2018). The V/V FcγRIIIa allotype is known to be present ~12% of the population (Musolino *et al*., 2022). Thus, patients with V/F or F/F allotypes exhibited poor ADCC effectiveness. P-TMab significantly increased the binding affinity to both FcγRIIIa allotypes, thereby enhancing the *in vitro* ADCC function (Fig. 6). Compared to the predominant afucosylated G0 type glycan found in P-TMab, Obinutuzumab produced from the GlycoMab® platform of GlycArt (now merged with Roche) yielded an afucosylated fraction of 30% to 50% (Mössner *et al*., 2010; Pereira *et al*., 2018). This mAb is the first Fc-glycoengineered anti-CD20 mAb approved by the FDA. Other afucosylated mAbs approved by the FDA include Mogamulizumab and Benralizumab, which are produced from the Potelligent® platform. This platform has also demonstrated improved ADCC efficacies through Fc-afucosylation (Kolbeck *et al*., 2010; Duvic *et al*., 2015). In the future, deliberate modification of therapeutic protein glycosylation is expected to become more prevalent due to glyco-engineering strategies (Dammen-Brower *et al*., 2022). Specific glyco-engineered platforms capable of attaching unique N-glycans such as G1 or G0F could be utilized for specific purposes related to Fc effector function and stability.

P-TMab displayed less liver uptake and more efficient tumor targeting than TMab (Fig. 7), which might be due to the homogeneous N-glycan type (mainly G0 type) in the Fc region of P-TMab. The asialoglycoprotein receptor and mannose receptor in hepatocytes are known to respectively recognize terminal galactose and mannose N-glycan forms attached to glycoproteins, causing rapid clearance (Wright and Morrison, 1994; Svecla *et al*., 2023). Furthermore, a pharmacokinetic study on N-glycan types of IgG in mouse showed that degalactosylated IgG with terminal GlcNAc has a significantly longer half-life (Newkirk *et al*., 1996). These indicate that the functions and *in vivo* fate of glycoproteins are significantly affected by the N-glycan structure. Therefore, we suggest that the PhytoRice® platform could be a superior therapeutic platform for producing IgG1, enhancing ADCC efficacy and half-life.

In terms of productivity, our PhytoRice®-based TMab production reached 91.5 mg/L. Recently, the production of GFP from Hulk cells developed in BY-2 cell exceeded 1 g/L (Häkkinen *et al*., 2018). This cell line was developed through repeated selection of the original transgenic cell lines, reflecting a more focused effort to isolate high-production cells, which is promising. Given that high-productivity CHO cells were only capable of producing minimal amounts of recombinant proteins during their initial development, it is anticipated that the productivity of current plant-based recombinant proteins can be enhanced even further. CHO cell engineering has been evolving for over six decades since it was established by Theodore Puck in 1956. Modifications to medium composition, culture systems, processing, and genetic manipulation have been implemented to overcome yield issues (Wurm, 2004). It indicates that a plant cell-based platform could also increase productivity in the near future. Recently, it has been reported that the knock-in technology was used to precisely insert GFP behind the endogenous *RAmy3D* promoter in rice, aiming to increase productivity in the sugar starvation-inducible system (Nguyen *et al*., 2022). The application of targeted integration strategy could lead to innovation and increased productivity in the plant cell platform in the near future.

**Materials and Methods**

**Plant material and growth condition**

The Rice Dongjin (DJ) cultivar and glyco-engineered PhytoRice® were utilized for *Agrobacterium*-mediated transformation. Rice mature seeds, sterilized with 1.5% NaOCl for 40 minutes, were grown on 2N6 media containing 2 mg/L 2,4-D at 28°C for 3-4 weeks under dark conditions. The formed calli were then used as materials for the transformation to construct PhytoRice®. Selected callus lines were maintained by subculturing every 2-3 weeks in dark conditions at 28°C.

**Design of target sequences and vector constructions**

To knock out 8 genes (*β1,2-XylT*, *α1,3-FucT*, *β1,3-GalT*, *α1,4-FucT*, and 4 putative hexosaminidase genes) involved in N-glycosylation, one specific target sequence per gene was selected using the CRISPR-P gRNA design tool (Liu *et al*., 2017). The information about the selected target sequences and target genes is summarized in Table 1. Polycistronic gRNA sequences, including 8 target sequences, were aligned as previously described (Xie *et al*., 2015), and two rice U6 promoters were inserted to drive four gRNAs each (Table S1). The multiplex gRNA sequences, which include *Hind*III/*Xba*I recognition sequences at their respective 5' and 3'-ends, were synthesized by GenScripts (Piscataway, NJ, USA). The synthesized multiplex gRNA sequences were inserted into the pSB11-Cas9-HPT vector after digestion with *Hind*III/*Xba*I (Fig. 1a). The engineered vector, pPM101, was introduced into *Agrobacterium tumefaciens* (LBA4404) using the triparental mating method (Wise *et al*., 2006)..

To construct the TMab expression vector, the sequences encoding the light chain (LC) and heavy chain (HC) were fused with the *RAmy3E* gene signal peptide (MGKHHVTLCCVVFAVLCLASSLAQA). These sequences were codon-optimized for expression in rice and synthesized by GeneArt® (Thermo Fisher Scientific, Waltham, MA, USA). After amplifying full-length sequences of each gene through PCR, the resulting fragments were digested with *Sal*I/*Sac*I. Subsequently, the digested fragments were individually inserted into the pMyn75 vector, which contains the *RAmy3D* gene promoter-driven expression system, to create the pMyn75-TMab LC and pMyn75-TMab HC vectors. To make a co-expression vector, the LC expression cassette (pro*RAmy3D*::TMab-LC::Ter*RAmy3D*) was amplified by PCR and then inserted into the pMyn75-TMab HC vector after digestion with *Eco*RI, resulting in the formation of pMyn75-TMab. After digestion with *Hind*III, the fragment containing the LC and HC expression cassettes from pMyn75-TMab was purified and subsequently inserted into the pCleanB vector, which contains the phosphinothricin (PPT)-resistant gene. This resulting construct was named the pPM102 vector (Fig. 2a).

**Plant transformation and selection**

Rice seeds were sterilized with 70% ethanol and 1.5% sodium hypochlorite, and then placed onto 2N6 media containing 2 mg/L 2,4-D (callus-inducing media, CIM) to induce callus formation from the scutellum. Using embryogenic calli derived from the scutellum or PhytoRice®, *Agrobacterium*-mediated transformation was performed as previously described (Hiei and Komari, 2008; Kumar *et al*., 2017). The transgenic calli were selected on CIM containing 40 mg/L of hygromycin for pPM101 and 15 mg/L of PPT for pPM102. The subculture was conducted every two weeks.

**Polymerase chain reaction (PCR)**

To analyze the genome editing patterns, PCR was performed around each target region using genomic DNA extracted from the calli. Each primer set was designed to include a 400-500 bp-long target region. The PCR products eluted using the Expin PCR SV mini clean-up kit (GeneAll, Seoul, South Korea) were sequenced using the Sanger sequencing method. To screen TMab-expressing lines, PCR was performed using the TMab LC primer set after extracting genomic DNA from PPT-resistant calli using a modified CTAB method (Kim *et al*., 2011). The primer sets used for PCR and detailed PCR conditions are summarized in Table S6.

**Analysis of genome editing efficiency**

Using the sequencing results, we analyzed INDELs in the target regions using the Inference of CRISPR Edits (ICE) analysis tool (https://ice.synthego.com/#/) (Hsiau *et al*., 2019).

**Immunoblotting**

To investigate the expression of P-TMab in the selected lines, calli (approximately 100 mg) that had been incubated for 7 days on induction media without sucrose were ground in 1 volume of PBS buffer (pH 7.4) containing 1x cOmplete (Roche, Indianapolis, IN, USA). After centrifuging cell lysates at 14,000 rpm at 4°C for 10 minutes, the obtained samples were run on a 7.5% SDS/PAGE gel. The separated proteins were then transferred to a nitrocellulose membrane using the Trans-blot Turbo Transfer System (Bio-Rad, Hercules, CA, USA). Interaction with anti-human IgG-HRP (1:5,000; Invitrogen, Waltham, MA, USA) was performed for 30 minutes after the blocking step using a 5% skim milk-PBST solution. The target protein was detected using ImageQuant™ LAS 500 (Cytiva, Marlborough, MA, USA) following ECL treatment.

To investigate P-TMab expression in the selected lines,calli (about 100 mg) 7 day-incubated on induction media subtracting sucrose were ground in 1 volume of PBS buffer (pH 7.4) including 1 x cOmplete (Roche, Indianapolis, IN, USA). After cell lysates obtained by centrifugation at 14,000 rpm at 4°C for 10 min were run in 7.5% SDS/PAGE gel, the separated proteins were transferred into nitrocellulose membrane using Trans-blot Turbo Transfer System (Bio-Rad, Hercules, CA, USA). Interaction with anti-human IgG-HRP diluted 1:5,000 (Invitrogen, Waltham, MA, USA) was performed for 30 min after blocking step with 5% skim milk-PBST solution. The target protein via ECL treatment was detected using ImageQuant™ LAS 500 (Cytiva, Marlborough, MA, USA).

**P-TMab induction in rice suspension cell culture**

Calli were finally selected from the P-TMab-expressing line and inoculated in N6 liquid media containing 2 mg/L 2,4-D and 0.02 mg/L kinetin. The cultures were then cultivated at 28°C with shaking at 110 rpm. The suspension culture was subcultured every 7 days by adding one volume of inoculum to four volumes of N6 liquid media. The established suspension cells were used to induce P-TMab. Suspension cells were harvested by centrifugation and then inoculated into N6 liquid media without sucrose (induction liquid media) to achieve a 50% (V/V) cell density. The cells were then incubated at 28°C with shaking at 110 rpm for 7 days.

**Enzyme-linked immunosorbent assay (ELISA)**

Both cells and spent media were harvested 5 days after P-TMab induction. Cell lysates were then prepared using 1xPBS (pH 7.4) containing 1x cOmplete protease inhibitor cocktail (Roche, Indianapolis, IN, USA). The quantity of P-TMab was measured using the Human IgG total ELISA kit (Invitrogen, Waltham, USA). For the assay, all samples were diluted at a ratio of 1:20000. Then, 100 µl of each sample and 50 µl of horseradish peroxidase (HRP)-conjugated anti-human total IgG monoclonal antibody, diluted at a ratio of 1:100, were added to the microwell plates coated with monoclonal antibody to human total IgG. After incubating for 1 hour at room temperature, the color reaction was carried out using tetramethylbenzidine for 30 minutes. The absorbance of the samples at 450 nm was measured using a microplate reader. A standard curve was generated using a 5-parameter curve fit in SoftMax Pro 7.1, and the quantities of P-TMab were subsequently calculated. All samples were analyzed in both biological and technical duplicates.

**Purification of P-TMab**

The spent media was filtered using a Miracloth (Merck Life Sciences, Darmstadt, Germany) and then passed through a 0.2 μm depth filter. This was followed by ultrafiltration using Vivaflow (50 MWCO, Sartorius, Göttingen, Germany). P-TMab was purified according to the method described previously (Ma *et al*., 2015). The quantity of purified TMab was determined using NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA), and its quality was assessed using SDS-Polyacrylamide gel electrophoresis.

**Full length amino acid sequencing analysis**

P-TMab and TMab (Herceptin®; purchased from Roche, Basel, Switzerland) were subjected to trypsin or Glu-C treatment under reducing conditions. The cleaved peptide was separated using a reverse-phase column (C18) via RP-UPLC. Mass spectrometry data of peptide peaks separated on UPLC was obtained through MS1 analysis, and the molecular weight of the peptide determined from the MS data identified it as a peptide with the expected sequence. The peptide's amino acid sequence was determined through analysis of the fragmentation spectrum. After fragmenting the peptides, information from the UPLC-MS1 analysis was used to identify the peptide peaks and determine the sequence information of the peptides. The b-ions and y-ions, cut from the N-terminal and C-terminal regions, respectively, were generated by fragmentation through ESI (Q-TOF). The amino acid sequence was obtained by analyzing the masses of b-ions and y-ions.

**N-glycan structure analysis using MALDI-TOF**

To analyze the N-glycan pattern of secreted proteins, the spent media harvested from a 2-week suspension culture was filtered through a 0.2 μm pore-sized membrane and then concentrated using a 5 kDa cut-off Vivaspin (Sartorius, Göttingen, Germany). The total secreted proteins or purified TMab (200 µg) were digested with 20 µg of trypsin in a reaction buffer (100 mM Tris-HCl, pH 8.2, 1 mM CaCl2) at 37°C for 16 hours. The trypsin-digested peptides were desalted using a reverse-phase Sep-Pak C18 cartridge (Restek, Centre County, PA, USA) and then lyophilized. The glycopeptides were resuspended in a 50mM sodium phosphate buffer (pH 5.2) and then incubated with 1 U of peptide-N-glycosidase A (New England Biolabs, Ipswich, MA, USA) at 37°C for 18 hours. The N-linked glycans released were purified from the peptides using a Sep-Pak C18 (Restek, Centre County, PA, USA) with a 5% acetic acid elution solution. The samples were lyophilized and then permethylated. The permethylated glycans were subsequently purified using a Sep-Pak C18 (Restek, Centre County, PA, USA) and then freeze-dried for analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).

**N-glycan structure analysis using UPLC-FLD method**

The deglycosylation of P-TMab and TMab, N-glycan labeling, and purification were performed using the Glycoworks RapiFluor-MS N-Glycan Kit (Waters, Milford, MA, USA), following the manufacturer's instructions. The intact mAb Mass Check Standard (186008843; Waters, Milford, MA, USA) was used as the control standard. For the separation of the labeled N-glycan, the Ultra Performance Liquid Chromatograph (UPLC I-class system; Waters, Milford, MA, USA) was used with the ACQUITY UPLC Glycan BEH amide (130 Å, 1.7 µm, 2.1 x 150 mm; Waters, Milford, MA, USA) column and the fluorescence detector. The following gradient conditions were used (mobile phase A, 50 mM ammonium formate solution, pH 4.4; mobile phase B, 100% acetonitrile). The gradient profile was as follows: 0-35 min, 75% to 54% mobile phase B, flow rate of 0.4 mL/min; 35-36.5 min, 54% to 0% B, 0.4 to 0.2 mL/min; 36.5-39.5 min, 0% B, 0.2 mL/min; 39.5-43.1 min, 0% to 75% B, 0.2 mL/min; 43.1-47.6 min, 75% B, 0.2 to 0.4 mL/min; 47.6-55 min, 75% B, 0.4 mL/min. The column oven temperature was maintained at 60°C, and the sample injection volume was 10 µL. Fluorometric detection was performed using excitation and emission wavelengths of 265 nm and 425 nm, respectively. The molecular mass of the labeled N-Glycan was determined using the Orbitrap mass spectrometer (LTQ Orbitrap; Thermo Fisher Scientific, San Jose, CA, USA) equipped with the UPLC system (UltiMate™ 3000; Thermo Fisher Scientific, San Jose, CA, USA).

**Protein binding affinity assay (SPR and BLI)**

The binding of TMab and P-TMab to human FcγRIIIa variants (V158 and F158 allotypes) (10389-H08H1 and 10389-H08H; Sino Biological, Beijing, China) was assessed using a Biacore X100 surface plasmon resonance biosensor (Cytiva, Marlborough, MA, USA). CM5 chips were covalently coupled with *S. aureus* Protein A (Merck P6031; Merck Life Sciences, Darmstadt, Germany) to achieve a response level of 3000 RU. In a standard assay, 750-1000 RU of antibody were immobilized on the active channel (Fc2), and the receptor (FcγRIIIa 25-800nM) was flowed over both channels at a rate of 30 μl/min. The resulting data were fitted using a Langmuir 1:1 model (BIAEvaluation v.3.2; Cytiva, Marlborough, MA, USA).

***In vitro* antiproliferation assay**

BT-474 cells were seeded at 4⨯103 cells per well in a 96-well plate. Cells were treated with TMab or P-TMab at various concentrations and then incubated for 72 hours. After adding CCK-8 solution (Dojindo, Rockville, MD, USA), the cells were further incubated for 2 hours. The absorbance was measured at 450 nm using a microplate reader (ThermoFisher Scientific, Hampton, NH, USA).

**ADCC assay**

The HER2-positive cell line, BT474 cells, was seeded at a density of 1.25×104 cells per well in a 96-well plate and then incubated in a CO2 incubator for 24 hours. ADCC buffer containing 4% Low IgG serum (Promega, Madison, MI, USA), was treated with TMab and P-TMab antibodies at various concentrations. Jurkat cells were treated at a concentration of 3×106 cells/mL and then incubated for 24 hours. After the incubation, Bio-Glo reagent (Promega, Madison, MI, USA) was added, and luminescence was measured using a Luminoskan (Thermo Scientific, Waltham, MA USA).

**Mouse xenograft tumor model and nuclear medicine imaging**

Female nude mice (6-8 weeks old) were obtained from Orient Bio (Sungnam, South Korea) and acclimated for 1 week. All mice were housed in specific-pathogen-free conditions at a controlled temperature of 23 ± 2°C with a 12-hour light/dark cycle. Animal experiments were conducted following ethical guidelines and approved by the Institutional Animal Care and Use Committee of Seoul National University Hospital. To promote BT-474 breast cancer tumor cells in nude mice, estrogen supplementation is necessary. Therefore, mice were subcutaneously injected with estradiol pellets that released 2.5 mg of estrogen for 60 days (Innovative Research of America, Sarasota, FL, USA) into the dorsal cervicis before tumor inoculation. BT-474 cells (2×10^7 cells) were subcutaneously injected into the right flank of a mouse.

For conjugation with radioactive isotopes, antibodies were reduced by adding 1 mM of tris(2-carboxyethyl)phosphine (TCEP) for 2 h at 37°C, then 20 nmol/μl of DBCO-PEG4-maleimide (Dibenzocyclooctyne-PEG4-maleimide) was added and incubated at room temperature for 2 h. 18 nmol of 3-azidopropyl-NOTA (3-azidopropyl-1,4,7-triaza-cyclononane-1,4,7-triacetic acid) was added to 111InCl3 and the reaction mixture was incubated at 70°C for 10 min in a heating block. Subsequently, 3-azidopropyl-NOTA-111In was added to DBCO-antibodies for 1 h at 37°C in a heating block. The labeling efficiency at each step was determined using Instant Thin Layer Chromatography (ITLC-SG). Strips were counted with a Bio-Scan AR-2000 System Imaging Scanner (Bio-Scan Inc., Washington D.C., USA).

111In-labeled TMab or P-TMab antibody (7.34 MBq ± 0.758) was administered by tail vein injection to BT-474 tumor-bearing mice and SPECT/CT images were acquired using nanoSPECT plus (Mediso, Budapest, Hungary) at 0, 6, 24, and 48 h post injection.

**References**

Arnould L, Gelly M, Penault-Llorca F, et al. (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259–67.

Arya SS, Kumari DD, Rookes JE, Cahill DM, Lenka SK (2021) Rice cell suspension culture as a model for producing high-value recombinant proteins and plant specialized metabolites. Plant Cell, Tissue and Organ Culture 145: 463–486.

Bang YJ, Van CE, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697.

Buyel JF, Twyman RM, Fischer R (2017) Very-large-scale production of antibodies in plants: The biologization of manufacturing. Biotechnology Advances 35: 458-465.

Castilho A and Steinkellner H (2012) Glyco‐engineering in plants to produce human‐like N‐glycan structures. Biotech J 7: 1088-1098

Castilho A, Beihammer G, Pfeiffer C, Goritzer K, Montero-Morales L, Vavra U, Maresch D, Grunwald-Gruber C, Altmann F, Steinkellner H, Strasser R (2018) An oligosaccharyltransferase from Leishmania major increases the N-glycan occupancy on recombinant glycoproteins produced in *Nicotiana benthamiana*. Plant Biotechnology Journal 16: 1700–1709.

Chen Q, Davis KR (2016) The potential of plants as a system for the development and production of human

biologics. F1000Research 5.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648.

Corbin JM, McNulty MJ, Macharoen K, McDonald KA, Nandi S (2020) Technoeconomic analysis of semicontinuous bioreactor production of biopharmaceuticals in transgenic rice cell suspension cultures. Biotechnol Bioeng. 117:3053-3065.

Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, Black A, Passmore D, Moldovan-Loomis C, Srinivasan M, Cuison S, Cardarelli PM, Dickey LF (2006) Glycan optimization of a human monoclonal antibody in the aquatic plant *Lemna minor*. *Nat Biotechnol* **24**, 1591–1597.

Dammen-Brower K, Epler P, Zhu S, Bernstein ZJ, Stabach PR, Braddock DT, Spangler JB, Yarema KJ (2022) Strategies for Glycoengineering Therapeutic Proteins. Front. Chem. 10:863118.

Donini R, Haslam SM, Kontoravdi C (2021) Glycoengineering Chinese hamster ovary cells:

a short history. Biochemical Society Transactions 49: 915–931.

Doran PM (2006) Foreign protein degradation and instability in plants and plant tissue cultures. Trends Biotechnol 24: 426-432.

Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R (2015) Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 125: 1883–9.

Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. MAbs. 7: 9–14.

Fanata WID, Lee KH, Son BH, Yoo JY, Harmoko R, Ko KS, Ramasamy NK, Kim KH, Oh DB, Jung HS, Kim JY, Lee SY, Lee KO (2013) N-glycan maturation is crucial for cytokinin-mediated development and cellulose synthesis in *Oryza sativa*. Plant J 73: 966-979.

Fox JL (2012) First plant-made biologic approved. Nat. Biotechnol. 30: 472.

Fiedler W, Stoeger H, Perotti A, et al. (2018) Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. ESMO Open 3: e000381.

Gomord V, Faye L (2004) Posttranslational modification of therapeutic proteins in plants. Curr Opin Plant Biol 7:171-181.

Gomord V, Fitchette AC, Menu-Bouaouiche L, Saint-Jore-Dupas C, Plasson C, Michaud D, Faye L (2010) Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnol J 8:564–587.

Göritzer K, Grandits M, Grünwald-Gruber C, Figl R, Mercx S, Navarre C, Ma JK, Teh AY (2022). Engineering the N-glycosylation pathway of Nicotiana tabacum for molecular pharming using CRISPR/Cas9. Frontiers in plant science 13: 1003065.

Grohs BM, Niu Y, Veldhuis LJ, Trabelsi S, Garabagi F, Hassell JA, McLean MD, Hall JC (2010) Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells. J Agric Food Chem. 58:10056-63.

Gül N, van Egmond M. (2015) Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res 75: 5008–13.

Hanania U, Ariel T, Tekoah Y, Fux L, Sheva M, Gubbay Y, Weiss M, Oz D, Azulay Y, Turbovski A, Forster Y, Shaaltiel Y (2017) Establishment of a tobacco BY2 cell line devoid of plant‐specific xylose and fucose as a platform for the production of biotherapeutic proteins. Plant biotech J 15: 1120-1129.

Häkkinen ST, Reuter L, Nuorti N, Joensuu JJ, Rischer H and Ritala A (2018) Tobacco BY-2 Media Component Optimization for a Cost-Efficient Recombinant Protein Production. Front. Plant Sci. 9:45.

Harmoko R, Yoo JY, Ko KS, Ramasamy NK, Hwang BY, Lee EJ, Kim HS, Lee KJ, Oh DB, Kim DY, Lee S, Li Y, Lee SY, Lee KO (2016) N-glycan containing a core α1,3-fucose residue is required for basipetal auxin transport and gravitropic response in rice (Oryza sativa). New Phytol 212: 108-22

Herman X, Far J, Peeters M, Quinton L, Chaumont F, Navarre C (2023) In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells. Plant biotechnology journal 21(9): 1773–1784.

Hiatt A, Caffferkey R, Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342, 76–78 (1989).

Hiei Y, Komari T (2008) *Agrobacterium*-mediated transformation of rice using immature embryos or calli induced from mature seed. Nature Protocols 3: 824-834.Holtz BR, Berquist BR, Bennett LD, Kommineni VJM, Munigunti RK, White EL, Wilkerson DC, Wong KYI, Ly

LH, Marcel S (2015) Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals. Plant Biotechnology Journal (2015) 13, pp. 1180–1190.

Hsiau T, Conant D, Rossi N, Maures T, Waite K, Yang J, Joshi S, Kelso R, Holden K, Enzmann BL, Stoner R (2019) Inference of CRISPR Edits from Sanger Trace Data. BioRxiv **doi:** https://doi.org/10.1101/251082.

Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N. Engl. J. Med. 357: 39–51.

Hughes D, Gonzalez D, Maegawa G, Bernat JA, Holida M, Giraldo P, Atta MG, Chertkoff R, Alon S, Almon EB, Rocco R, Goker-Alpan O (2023). Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease. Genetics in Medicine, In press 100968.

Jung JW, Shin JH, Lee WK, Begum H, Chang MW, et al. (2021) Inactivation of the β (1, 2)-xylosyltransferase and the α (1, 3)-fucosyltransferase gene in rice (*Oryza sativa*) by multiplex CRISPR/Cas9 strategy. Plant Cell Report 40(6):1025-1035.

Jung JW, Kim SR (2023) β1,3-galactosyltransferase on chromosome 6 is essential for the formation of Lewis a structure on N-glycan in Oryza sativa. Transgenic Res. https://doi.org/10.1007/s11248-023-00360-y

Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF, Sliwkowski MX (2010) Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer. Cancer Res 70(11): 4481-4489.

Kim SR, Jeon JS, An G (2011) Development of an Efficient Inverse PCR Method for Isolating Gene Tags from T-DNA Insertional Mutants in Rice. In: Pereira, A. (eds) Plant Reverse Genetics. Methods in Molecular Biology, vol 678. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-682-5\_11

Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M (1997) Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 90: 1109–14.

Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL (2010) MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 125: 1344-53 e2.

Komarova TV, Kosorukov VS, Frolova OY, Petrunia IV, Skrypnik KA, Gleba YY, , Dorokhov YL (2011) Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth. PLoS ONE 6: e17541.

Komarova TV, Sheshukova EV, Kosobokova EN, Kosorukov VS, Shindyapina AV, Lipskerov FA, Shpudeiko PS, Byalik TE, Dorokhov YL (2019) The biological activity of bispecific trastuzumab/pertuzumab plant biosimilars may be drastically boosted by disulfiram increasing formaldehyde accumulation in cancer cells. Sci Rep 9, 16168.

Kumar M, Choi J, An G, Kim SR (2017) Ectopic expression of *OsSta2* enhances salt stress tolerance in rice. Front. Plant Sci. 8: 316.

Kwon JY, Cheon, SH, Lee HR, Han JY, Kim DI (2009) Production of biopharmaceuticals in transgenic plant cell suspension cultures. J Plant Biotechnol 36:309–319.

Liebminger, E., Veit, C., Pabst, M., Batoux, M. et al. (2011) Beta-N-acetylhexosaminidases HEXO1 and HEXO3 are responsible for the formation of paucimannosidic N-glycans in Arabidopsis thaliana. J Biol Chem 286: 793–802

Liu H, Ding Y, Zhou Y, Jin W, Xie K, Chen LL (2017) CRISPR-P 2.0: an improved CRISPR/Cas9 tool for genome editing in plants. Mol Plant 10: 530-532.

Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC (2020) Development of therapeutic antibodies for

the treatment of diseases. Journal of Biomedical Science (2020) 27:1.

Ma B, Guan X, Li Y, Shang S, Li J, Tan Z (2020) Protein Glycoengineering: An Approach for Improving Protein Properties. Frontiers in Chemistry 8: 622.

Ma JKC, Drossard J, Lewis D, Altmann F, Boyle J, Christou P, Cole T, Dale P, van Dolleweerd CJ, Isitt V, Katinger D, Lobedan M, Mertens H, Paul MJ, Rademacher T, Sack M, Hundleby PAC, Stiegler G, Stoger E, Twyman RM, Vcelar B, Fischer R (2015) Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. Plant Biotechnol J 13: 1106-1120.

McLean MD (2017) Trastuzumab Made in Plants Using vivoXPRESS® Platform Technology. J Drug Des Res 4(5): 1052.

Mercx S, Smargiasso N, Chaumont F, De Pauw E, Boutry M, Navarre C (2017) Inactivation of the β(1,2)-xylosyltransferase and the α(1,3)-fucosyltransferase genes in Nicotiana tabacum BY-2 Cells by a Multiplex CRISPR/Cas9 Strategy Results in Glycoproteins without Plant-Specific Glycans. Front Plant Sci 8: 403.

Mirasol F (2022) Emerging Plant-based Platform for Biomanufacturing. BioPharm International 35(5) 12.

Moro Pe´rez L, Rodrı´guez Taño AdlC, Martı´n Ma´rquez LR, Go´mez Pérez JA, Valle Garay A, Blanco Santana R (2019) Conformational characterization of a novel anti-HER2 candidate antibody. PLoS ONE 14(5): e0215442.

Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22): 4393-402.

Musolino A, Gradishar WJ, Rugo HS, et al. (2022) Role of Fcγ receptors in HER2-targeted breast cancer therapy. J Immunother Cancer 10: e003171.

Pereira NA, Chan KF, Lin PC, Song Z (2018) The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. mAbs 10: 693-711.

Nebija D, Noe CR, Urban E, Lachmann B. (2014) Quality control and stability studies with the monoclonal antibody, trastuzumab: application of 1D- vs. 2D-gel electrophoresis. Int J Mol Sci. 2014; 15(4):6399–411.

Newkirk MM, Novick J, Stevenson MM, Fournier MJ & Apostolakos P (1996) Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol 106: 259–264.

Nguyen TM, Lu CA, Huang LF (2022) Applications of CRISPR/Cas9 in a rice protein expression system via an intron-targeted insertion approach. Plant Sci. 315: 111132.

Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore CA, Johnson S, Bonvini E (2011) Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcg receptor binding properties. Breast Cancer Research 13:R123.

Ridgley LA, Falci Finardi N, Gengenbach BB, Opdensteinen P, Croxford Z, Ma JK, Bodman-Smith M, Buyel JF, Teh AY (2023) Killer to cure: Expression and production costs calculation of tobacco plant-made cancer-immune checkpoint inhibitors. Plant Biotechnol J. 21(6):1254-1269.

Rugo HS, Im SA, Cardoso F, et al. (2021) Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol.

Ruocco V, Strasser R (2022) Transient Expression of Glycosylated SARS-CoV-2 Antigens in *Nicotiana benthamiana*. Plants 11(8):1093.

Santos RB, Abranches R, Fischer R, Sack M, Holland T (2016) Putting the spotlight back on plant suspension cultures. Front Plant Sci 7: 297.

Shanmugaraj B, Bulaon CJI, Phoolcharoen W (2020) Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants 9: 842.

Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 277: 26733–40.

Shin YJ, Chong YJ, Yang MS, Kwon TH (2011) Production of recombinant human granulocyte macrophage-colony stimulating factor in rice cell suspension culture with a human-like N-glycan structure. Plant Biotechnol J 9: 1109-1119.

Shin YJ, Castilho A, Dicker M, et al. (2017) Reduced paucimannosidic N-glycan formation by suppression of a specific β-hexosaminidase from Nicotiana benthamiana. Plant Biotechnol J 15:197-206.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.

Stelter S, Paul MJ, Teh AYH, Grandits M, Altmann F, Vanier J, Bardor M, Castilho A, Allen RL, Ma JK-C (2020) Engineering the interactions between a plant-produced HIV antibody and human Fc receptors. Plant Biotechnol J 18: 402-414.

Strasser R, Bondili J, Schoberer J, Svoboda B, Liebminger E, Glossl J, Altmann F et al. (2007) Enzymatic properties and subcellular localization of Arabidopsis beta-N-acetylhexosaminidases. Plant Physiol 145: 5–16.

Strasser R, Stadlmann J, Schähs M, Stiegler G, Quendler H, Mach L, Glössl J, Weterings K, Pabst M, Steinkellner H (2008) Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnology Journal 6: 392-402.

Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M (2007) A Nonfucosylated Anti-HER2 AntibodyAugments AntibodyDependent Cellular Cytotoxicity in Breast Cancer Patients. Clin Cancer Res 13(6): 1875-1882.

Svecla M, Nour J, Bladergroen MR, Nicolardi S, Zhang T, Beretta G, Wuhrer M, Norata GD, Falck D (2023) Impact of Asialoglycoprotein Receptor and Mannose Receptor Deficiency on Murine Plasma N-glycome Profiles. Mol Cell Proteomics (2023) 22(9) 100615.

Takano S, Matsuda S, Funabiki A, Furukawa JI, Yamauchi T, Tokuji Y, Nakazono M, Shinohara Y, Takamure I, Kato K (2015) The rice RCN11 gene encodes β1,2-xylosyltransferase and is required for plant responses to abiotic stresses and phytohormones. Plant Sci 236: 75-88.

Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17: 176–180.

Wise AA, Liu Z, Binns AN (2006) Three methods for the introduction of foreign DNA into *Agrobacterium*. In: Wang K (ed) *Agrobacterium* protocols, vol 1, 2nd edn. Humana Press, Totowa, NJ, pp 43–54.

Wright A, Morrison SL (1994) Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med. 180:1087-96.

Wurm, FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat

Biotech 22: 1393-1398.

Xie K, Minkenberg B,Yang Y (2015) Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system. PNAS 112: 3570-3575.

Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87: 614–622.

**Figure legend**

**Figure 1.** Construction and characterization of CRISPR-Cas9 based glyco-engineered rice cell lines. (A) The diagram of pPM101. The multiplex CRISPR-Cas9 vector that expresses Polycistronic single guide RNAs (sgRNAs) targeted into 8 genes involved in plant-specific N-glycosylation pathway was was constructed. The two expression cassettes of polycistronic sgRNA sequences driven by rice U6 promoter were inserted into CRISPR-Cas9 vector, named pPM101. The detailed information of sgRNAs used was summarized in Table 1. (B) INDEL efficiencies occurred in 8 genes from final selected cell lines. pPM101 was integrated into rice genome via *Agrobacterium*-mediated transformation method. The cells (PMOsC1 and 2) were finally selected using callus line showing highest INDEL efficiency. The efficiency of genome-editing was analyzed by ICE tool (https://ice.synthego.com/#/). (C) N-glycan profile of PMOsC1, named PhytoRice®. The N-glycan structures purified from total secreted proteins were analyzed using MALDI-TOF. In PhytoRice®, GnGn form was detected, indicating entire elimination of plant-specific N-glycan (Bottom panel), whereas various N-glycan structures containing plant specific sugar such as β1,2-xylose, α1,3 or α1,4-fucose and β1,3-galactose were found in WT (Upper panel).

**Figure 2.** Construction of TMab expression vector and screening of PhytoRice®-based TMab-expressing rice cell lines. (A) The diagram of pPM102 expressing TMab. Codon-optimized TMab light chain (LC) and heavy chain (HC) genes were inserted into separate expression cassettes driven by the rice amylase 3D (*RAmy3D*) gene promoter, resulting in the construction of the TMab LC and HC co-expression vector, pPM102. (B) Genomic DNA (gDNA) PCR using the primer set for the TMab-LC gene. Approximately 700 base pair-sized bands were detected in phosphinothricin (PPT)-resistant callus lines. NC, WT callus (cv. Dongjin); PC, pPM102 plasmid; lane 1~12, PPT-resistant callus lines. (C) Immunoblotting of transgenic lines selected using gDNA PCR. The cells were cultured in induction media without sucrose for 7 days. Afterward, cell lysate was prepared and separated under non-reducing conditions in SDS/PAGE. The TMab was detected using rabbit α-human IgG-HRP at a dilution factor 1:5,000. The arrowhead indicates a TMab with a size of 150 kDa. NC, WT callus (Dongjin); PC, TMab (5 ng were loaded). (D) The induction of TMab using a secretory-Phyto101 suspension cell expression system. Cells well-grown under suspension cultivation were inoculated into induction liquid media and then incubated for 7 days. The spent media sample was separated under non-reducing conditions in a 7.5% SDS/PAGE (left panel), and immunoblotting was performed using rabbit anti-human IgG (right panel). D, days after induction; arrowhead, TMab; PC, TMab. (E) The quantification of TMab induced in Phyto101. ELISA was performed using cells induced for 5 days and their spent media. The standard deviation was calculated using the values from two biological replicates.

**Figure 3.** Purification and structural characterization of P-TMab from Phyto101. (A) P-TMab was purified using a 3-step method. P-TMab produced in the Phyto101 platform was sequentially purified using Protein A, anion exchange, and hydroxyapatite column chromatography. The purified P-TMab was separated under non-reducing (left panel) and reducing (right panel) conditions using a 7-15% gradient SDS/PAGE. Lane 1, P-TMab; Lane 2, TMab. (B-C) The conformational characteristics of P-TMab were examined using Circular Dichroism (CD) analysis. The secondary (B) and tertiary (C) structures of P-TMab and TMab were determined by Far-UV (195~250 nm) and near-UV (250~350 nm) CD absorption spectra.

**Figure 4.** The analysis of N-glycan attached to P-TMab. N-glycans purified from P-TMab and TMab were separated using the UPLC-FLD method. The GnGn (G0) form was exclusively found in the P-TMab (bottom panel), while heterogeneous N-glycan forms were detected in the TMab (upper panel).

**Figure 5.** The HER2-binding affinity and HER2-specific anti-proliferative effect of P-TMab. (A) Bio-layer interferometry (BLI) was used to measure and compare the binding affinity to HER2 of O-TMab, P-TMab and TMab. (B) CCK-8 assay. After treating BT-474 cells with O-TMab, P-TMab, or TMab for 72 hours, CCK-8 solution was added.

**Figure 6.** The binding affinity of P-TMab to FcγRIIIa variants and its *in vitro* ADCC assay. (A) The surface plasmon resonance (SPR) assay was used to assess the binding affinity of TMab and P-TMab to FcγRIIIa-F158 (upper box) and FcγRIIIa-V158 (middle box). The bottom panel provides a summary of the SPR assay. (B) *In vitro* ADCC assay. BT474 cells treated with TMab or P-TMab were co-cultured with Jurkat cells for 24 hours following the treatment.

**Figure 7.** *In vivo* biodistribution pattern of P-TMab. (A) TLC results confirming antibody labeling efficiency of the radioactive isotope 111Indium. (B) SPECT/CT images of 111In-labeled antibodies in BT474 tumor model.